Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barr syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Annexon, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

POTENTIAL TO BE THE FIRST TARGETED FAST-ACTING THERAPY FOR GBS, SETTING A NEW STANDARD OF CARE BLA SUBMISSION WITH U.S./EUROPEAN DATA FROM FORWARD TRIAL PLANNED IN 2026 BRISBANE, CALIF., JAN. 08, 2026 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING THE NEXT GENERATION PLATFORM OF TARGETED IMMUNOTHERAPIES AIMED AT NEUROINFLAMMATORY DISEASES THAT IMPACT NEARLY 10 MILLION PEOPLE WORLDWIDE, TODAY ANNOUNCED IT HAS SUBMITTED A MARKETING AUTHORIZATION APPLICATION (MAA) TO THE EUROPEAN MEDICINES AGENCY (EMA) FOR TANRUPRUBART FOR THE TREATMENT OF GUILLAIN-BARR SYNDROME (GBS).

ANNEXON SUBMITS TANRUPRUBART MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR GUILLAIN-BARR SYNDROME

BRISBANE, CALIF., JAN. 07, 2026 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING THE NEXT GENERATION PLATFORM OF TARGETED IMMUNOTHERAPIES AIMED AT NEUROINFLAMMATORY DISEASES THAT IMPACT NEARLY 10 MILLION PEOPLE WORLDWIDE, TODAY ANNOUNCED THAT DOUGLAS LOVE, PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE 44TH ANNUAL J.P.

ANNEXON BIOSCIENCES TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

BRISBANE, CALIF., DEC. 16, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (ANNEXON) (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM TARGETING NEUROINFLAMMATION ACROSS LIFE-CHANGING COMPLEMENT-MEDIATED DISEASES OF THE BODY, BRAIN, AND EYE, TODAY ANNOUNCED THAT IT HAS GRANTED INDUCEMENT TO A NEW NON-EXECUTIVE EMPLOYEE UNDER THE TERMS OF THE 2022 EMPLOYMENT INDUCEMENT AWARD PLAN. THE EQUITY AWARD WAS APPROVED ON DECEMBER 10, 2025, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

ANNEXON REPORTS INDUCEMENT GRANT TO NEW EMPLOYEE UNDER NASDAQ LISTING RULE 5635(C)(4)

BRISBANE, CALIF., NOV. 14, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (ANNEXON) (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM TARGETING NEUROINFLAMMATION ACROSS LIFE-CHANGING COMPLEMENT-MEDIATED DISEASES OF THE BODY, BRAIN, AND EYE, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 29,423,075 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE FULL EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE 4,326,922 ADDITIONAL SHARES OF COMMON STOCK, AT A PRICE TO THE PUBLIC OF $2.60 PER SHARE AND, IN LIEU OF SHARES OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 3,750,000 SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $2.599 PER SHARE, WHICH EQUALS THE PUBLIC OFFERING PRICE PER SHARE OF THE COMMON STOCK LESS THE $0.001 EXERCISE PRICE PER SHARE OF EACH PRE-FUNDED WARRANT.

ANNEXON ANNOUNCES CLOSING OF PUBLIC OFFERING AND FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES FOR GROSS PROCEEDS OF $86.25 MILLION

BRISBANE, CALIF., NOV. 12, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (ANNEXON) (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM TARGETING NEUROINFLAMMATION ACROSS LIFE-CHANGING COMPLEMENT-MEDIATED DISEASES OF THE BODY, BRAIN, AND EYE, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 25,096,153 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $2.60 PER SHARE AND, IN LIEU OF SHARES OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE 3,750,000 SHARES OF COMMON STOCK AT A PURCHASE PRICE OF $2.599 PER SHARE, WHICH EQUALS THE PUBLIC OFFERING PRICE PER SHARE OF THE COMMON STOCK LESS THE $0.001 EXERCISE PRICE PER SHARE OF EACH PRE-FUNDED WARRANT.

ANNEXON ANNOUNCES PRICING OF $75 MILLION PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

BRISBANE, CALIF., NOV. 12, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM TARGETING NEUROINFLAMMATION ACROSS LIFE-CHANGING COMPLEMENT-MEDIATED DISEASES OF THE BODY, BRAIN, AND EYE, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $75 MILLION OF SHARES OF ITS COMMON STOCK OR PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK IN LIEU THEREOF. ALL OF THE SECURITIES ARE BEING OFFERED BY ANNEXON. IN ADDITION, ANNEXON EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $11.25 MILLION OF SHARES OF ITS COMMON STOCK. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE PROPOSED OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE PROPOSED OFFERING.

ANNEXON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

LATE-STAGE NEUROINFLAMMATION PLATFORM ADVANCING GLOBAL REGISTRATIONAL PROGRAMS IN GUILLAIN-BARR SYNDROME ( GBS) AND GEOGRAPHIC ATROPHY (GA) CURRENT TANRUPRUBART GBS DOSSIER ON TRACK FOR MAA FILING IN JANUARY 2026; POTENTIAL TO BE THE FIRST APPROVED TARGETED AND FAST-ACTING THERAPY FOR THE TREATMENT OF GBS; CONTINUED FDA DISCUSSIONS REGARDING GENERALIZABILITY PACKAGE IN SUPPORT OF BLA FILING TOPLINE ARCHER II PIVOTAL DATA FOR VONAPRUMENT IN DRY AMD WITH GA ON TRACK FOR SECOND HALF OF 2026; POTENTIAL TO BE THE FIRST APPROVED VISION SPARING THERAPY FOR THE TREATMENT OF EIGHT MILLION GA PATIENTS WORLDWIDE ANX1502 COLD AGGLUTININ DISEASE (CAD) PROOF OF CONCEPT STUDY ONGOING WITH EXPECTED 2026 COMPLETION; POTENTIAL TO BE THE ONLY ORAL C1S INHIBITOR FOR THE TREATMENT OF MULTIPLE NEUROINFLAMMATORY AUTOIMMUNE DISEASES STRONG FINANCIAL POSITION AND EXECUTION EXTENDS OPERATIONS INTO 2027, THROUGH SEVERAL IMPORTANT MILESTONES, INCLUDING TANRUPRUBART GLOBAL GBS FILINGS, VONAPRUMENT TOPLINE GA PHASE 3 DATA, AND ANX1502 AUTOIMMUNE PROOF OF CONCEPT DATA BRISBANE, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM TARGETING NEUROINFLAMMATION ACROSS LIFE-CHANGING COMPLEMENT-MEDIATED NEUROINFLAMMATORY DISEASES OF THE BODY, BRAIN, AND EYE, TODAY HIGHLIGHTED PORTFOLIO PROGRESS, ANNOUNCED KEY ANTICIPATED MILESTONES AND REPORTED THIRD QUARTER 2025 FINANCIAL RESULTS.

ANNEXON REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS, PORTFOLIO PROGRESS AND KEY ANTICIPATED MILESTONES

BRISBANE, CALIF., AUG. 18, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX),A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM OF NOVEL THERAPIES FOR PEOPLE LIVING WITH DEVASTATING CLASSICAL COMPLEMENT-MEDIATED NEUROINFLAMMATORY DISEASES OF THE BODY, BRAIN, AND EYE, TODAY ANNOUNCED THAT IT HAS GRANTED INDUCEMENT TO A NEW NON-EXECUTIVE EMPLOYEE UNDER THE TERMS OF THE 2022 EMPLOYMENT INDUCEMENT AWARD PLAN. THE EQUITY AWARD WAS APPROVED ON AUGUST 11, 2025, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

TANRUPRUBART (FORMERLY ANX005) FOR GBS ADVANCING THROUGH REGULATORY INTERACTIONS; MAA SUBMISSION IN EUROPE ANTICIPATED IN FIRST QUARTER OF 2026; ONGOING DISCUSSIONS WITH FDA REGARDING GENERALIZABILITY PACKAGE TO SUPPORT A BLA ACCELERATED COMPLETION OF ENROLLMENT FOR GLOBAL PHASE 3 ARCHER II TRIAL OF VONAPRUMENT (FORMERLY ANX007) FOR DRY AMD WITH GA; SELECTED FOR EMA PRIME PRODUCT DEVELOPMENT CANDIDATE PILOT; TOPLINE ARCHER II DATA EXPECTED IN SECOND HALF OF 2026 ANX1502 FIRST-IN-KIND ORAL C1S INHIBITOR EXPOSURE EXCEEDED TARGET CONCENTRATION IN FASTED PATIENTS; EVALUATION IN RELATION TO FOOD INTAKE ONGOING IN PROOF-OF-CONCEPT CAD STUDY, UPDATE EXPECTED BY YEAR-END 2025 $227 MILLION IN CASH SUPPORTS OPERATIONS INTO THE FOURTH QUARTER OF 2026 THROUGH VONAPRUMENT TOPLINE PHASE 3 DATA IN GA BRISBANE, CALIF., AUG. 14, 2025 (GLOBE NEWSWIRE) -- ANNEXON, INC. (NASDAQ: ANNX), A BIOPHARMACEUTICAL COMPANY ADVANCING A LATE-STAGE CLINICAL PLATFORM OF NOVEL THERAPIES FOR PEOPLE LIVING WITH DEVASTATING CLASSICAL COMPLEMENT-MEDIATED NEUROINFLAMMATORY DISEASES OF THE BODY, BRAIN, AND EYE, TODAY HIGHLIGHTED PORTFOLIO PROGRESS, ANNOUNCED KEY ANTICIPATED MILESTONES AND REPORTED SECOND QUARTER 2025 FINANCIAL RESULTS.

ANNEXON REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS, PORTFOLIO PROGRESS AND KEY ANTICIPATED MILESTONES

NEW PILOT APPOINTS DESIGNATED PRODUCT DEVELOPMENT COORDINATOR TO NAVIGATE REGULATORY INTERACTIONS, RESPOND TO AD-HOC QUERIES, AND SUPPORT EVIDENCE PLANNING

ANNEXON SELECTED BY EMA TO PARTICIPATE IN PRODUCT DEVELOPMENT COORDINATOR PILOT FOR VONAPRUMENT (ANX007) FOR DRY AGE-RELATED MACULAR DEGENERATION WITH GEOGRAPHIC ATROPHY

EXPEDITED ENROLLMENT SURPASSING 630 TARGETED PARTICIPANTS UNDERSCORES THE STRONG DEMAND FOR A THERAPY FOCUSED ON VISION PRESERVATION

ANNEXON ANNOUNCES COMPLETION OF ENROLLMENT IN PIVOTAL PHASE 3 ARCHER II TRIAL OF VONAPRUMENT (FORMERLY ANX007) FOR DRY AGE-RELATED MACULAR DEGENERATION (AMD) WITH GEOGRAPHIC ATROPHY

DR. CLARK BRINGS 25 YEARS OF EXPERIENCE TREATING RETINA DISEASES AND DEVELOPING EMERGING THERAPIES AS A PRINCIPAL INVESTIGATOR IN OVER 70 CLINICAL TRIALS AND AS AN EARLY PIONEER OF VEGF INHIBITORS

ANNEXON BOLSTERS OPHTHALMOLOGY EXPERTISE WITH APPOINTMENT OF RETINA SPECIALIST LLOYD CLARK, M.D., AS PIVOTAL ANX007 PROGRAM ADVANCES IN DRY AGE-RELATED MACULAR DEGENERATION (AMD) WITH GEOGRAPHIC ATROPHY (GA)

Annexon, Inc.

ANNX

Price

Financial Reports

No items found.

Press Releases

Annexon, Inc.

ANNX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ANNX